Physician profile

Guy A Renvoize

Gastroenterology (Internal Medicine) · New York, NY

NPI 1902999287

$2,326.97

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$48.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $825.22 2019-2022
Abbvie INC. $796.84 2019-2023
Gilead Sciences, INC. $247.43 2019
Shionogi INC $172.45 2019
Janssen Biotech, INC. $113.27 2022
Redhill Biopharma INC. $89.27 2021-2022
Ironwood Pharmaceuticals, INC $47.59 2021
W. L. Gore & Associates, INC. $17.50 2021
Allergan, INC. $17.40 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Guy A Renvoize

$2,326.97

in general payments reported 2019-2025

Years
2019-2023
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/930171/guy-a-renvoize

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.